Abstract
Treatment of rats with cytokines has been associated with an increase in the circulating levels of endothelin 1 (ET-1). Here we show that administration of tumor necrosis factor alpha (TNF-alpha; 4 micrograms.kg-1) to anesthetized rats caused within 15 min a strong elevation in the circulating levels of ET-1. This was associated with a striking coronary vasoconstriction in hearts from these animals when they were removed and perfused in vitro by the Langendorff technique. This vasoconstriction was largely overcome by treatment with either the endothelin type A (ETA) receptor antagonist FR 139317 or antibody against ET-1. Furthermore, it was mimicked by in vivo exposure to exogenous ET-1. Endogenously produced TNF-alpha may also cause such a coronary vasoconstriction, for treatment with interleukin 2 (600 micrograms.kg-1) produced an increase in coronary perfusion pressure that correlated with the increases in circulating TNF-alpha. This coronary vasoconstriction was substantially reversed by treatment either with antibody against TNF-alpha or with FR 139317. We suggest, therefore, that cytokine-driven changes in the production of ET-1 are key events in the development of vascular pathologies.
Full text
PDF




Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Baydoun A. R., Peers S. H., Cirino G., Woodward B. Effects of endothelin-1 on the rat isolated heart. J Cardiovasc Pharmacol. 1989;13 (Suppl 5):S193–S196. doi: 10.1097/00005344-198900135-00054. [DOI] [PubMed] [Google Scholar]
- Boccoli G., Masciulli R., Ruggeri E. M., Carlini P., Giannella G., Montesoro E., Mastroberardino G., Isacchi G., Testa U., Calabresi F. Adoptive immunotherapy of human cancer: the cytokine cascade and monocyte activation following high-dose interleukin 2 bolus treatment. Cancer Res. 1990 Sep 15;50(18):5795–5800. [PubMed] [Google Scholar]
- Cernacek P., Stewart D. J. Immunoreactive endothelin in human plasma: marked elevations in patients in cardiogenic shock. Biochem Biophys Res Commun. 1989 Jun 15;161(2):562–567. doi: 10.1016/0006-291x(89)92636-3. [DOI] [PubMed] [Google Scholar]
- Filep J. G., Földes-Filep E., Rousseau A., Fournier A., Sirois P., Yano M. Endothelin-1 enhances vascular permeability in the rat heart through the ETA receptor. Eur J Pharmacol. 1992 Aug 25;219(2):343–344. doi: 10.1016/0014-2999(92)90318-x. [DOI] [PubMed] [Google Scholar]
- Fyhrquist F., Saijonmaa O., Metsärinne K., Tikkanen I., Rosenlöf K., Tikkanen T. Raised plasma endothelin-I concentration following cold pressor test. Biochem Biophys Res Commun. 1990 May 31;169(1):217–221. doi: 10.1016/0006-291x(90)91456-3. [DOI] [PubMed] [Google Scholar]
- Gomez-Sanchez C. E., Foecking M. F., Ferris M. W., Hieda H. S., Gomez-Sanchez E. P. Rat mesenteric artery endothelial cells in culture secrete ET-1. Life Sci. 1990;46(12):881–884. doi: 10.1016/0024-3205(90)90118-b. [DOI] [PubMed] [Google Scholar]
- Harrison V. J., Corder R., Anggård E. E., Vane J. R. Evidence for vesicles that transport endothelin-1 in bovine aortic endothelial cells. J Cardiovasc Pharmacol. 1993;22 (Suppl 8):S57–S60. doi: 10.1097/00005344-199322008-00017. [DOI] [PubMed] [Google Scholar]
- Haynes W. G., Webb D. J. Contribution of endogenous generation of endothelin-1 to basal vascular tone. Lancet. 1994 Sep 24;344(8926):852–854. doi: 10.1016/s0140-6736(94)92827-4. [DOI] [PubMed] [Google Scholar]
- Haynes W. G., Webb D. J. The endothelin family of peptides: local hormones with diverse roles in health and disease? Clin Sci (Lond) 1993 May;84(5):485–500. doi: 10.1042/cs0840485. [DOI] [PubMed] [Google Scholar]
- Hellman S. Immunotherapy for metastatic cancer. Establishing a 'proof of principle'. JAMA. 1994 Mar 23;271(12):945–946. [PubMed] [Google Scholar]
- Kanse S. M., Takahashi K., Lam H. C., Rees A., Warren J. B., Porta M., Molinatti P., Ghatei M., Bloom S. R. Cytokine stimulated endothelin release from endothelial cells. Life Sci. 1991;48(14):1379–1384. doi: 10.1016/0024-3205(91)90434-d. [DOI] [PubMed] [Google Scholar]
- Kaufmann H., Oribe E., Oliver J. A. Plasma endothelin during upright tilt: relevance for orthostatic hypotension? Lancet. 1991 Dec 21;338(8782-8783):1542–1545. doi: 10.1016/0140-6736(91)92370-h. [DOI] [PubMed] [Google Scholar]
- Kragel A. H., Travis W. D., Steis R. G., Rosenberg S. A., Roberts W. C. Myocarditis or acute myocardial infarction associated with interleukin-2 therapy for cancer. Cancer. 1990 Oct 1;66(7):1513–1516. doi: 10.1002/1097-0142(19901001)66:7<1513::aid-cncr2820660713>3.0.co;2-x. [DOI] [PubMed] [Google Scholar]
- Loesch A., Bodin P., Burnstock G. Colocalization of endothelin, vasopressin and serotonin in cultured endothelial cells of rabbit aorta. Peptides. 1991 Sep-Oct;12(5):1095–1103. doi: 10.1016/0196-9781(91)90065-w. [DOI] [PubMed] [Google Scholar]
- Macarthur H., Warner T. D., Wood E. G., Corder R., Vane J. R. Endothelin-1 release from endothelial cells in culture is elevated both acutely and chronically by short periods of mechanical stretch. Biochem Biophys Res Commun. 1994 Apr 15;200(1):395–400. doi: 10.1006/bbrc.1994.1462. [DOI] [PubMed] [Google Scholar]
- Masaki T., Kimura S., Yanagisawa M., Goto K. Molecular and cellular mechanism of endothelin regulation. Implications for vascular function. Circulation. 1991 Oct;84(4):1457–1468. doi: 10.1161/01.cir.84.4.1457. [DOI] [PubMed] [Google Scholar]
- Milner P., Bodin P., Loesch A., Burnstock G. Rapid release of endothelin and ATP from isolated aortic endothelial cells exposed to increased flow. Biochem Biophys Res Commun. 1990 Jul 31;170(2):649–656. doi: 10.1016/0006-291x(90)92141-l. [DOI] [PubMed] [Google Scholar]
- Miyauchi T., Yanagisawa M., Tomizawa T., Sugishita Y., Suzuki N., Fujino M., Ajisaka R., Goto K., Masaki T. Increased plasma concentrations of endothelin-1 and big endothelin-1 in acute myocardial infarction. Lancet. 1989 Jul 1;2(8653):53–54. doi: 10.1016/s0140-6736(89)90303-6. [DOI] [PubMed] [Google Scholar]
- Nora R., Abrams J. S., Tait N. S., Hiponia D. J., Silverman H. J. Myocardial toxic effects during recombinant interleukin-2 therapy. J Natl Cancer Inst. 1989 Jan 4;81(1):59–63. doi: 10.1093/jnci/81.1.59. [DOI] [PubMed] [Google Scholar]
- Ritz M. F., Stuenkel E. L., Dayanithi G., Jones R., Nordmann J. J. Endothelin regulation of neuropeptide release from nerve endings of the posterior pituitary. Proc Natl Acad Sci U S A. 1992 Sep 1;89(17):8371–8375. doi: 10.1073/pnas.89.17.8371. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Rosenberg S. A., Lotze M. T., Yang J. C., Aebersold P. M., Linehan W. M., Seipp C. A., White D. E. Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients. Ann Surg. 1989 Oct;210(4):474–485. doi: 10.1097/00000658-198910000-00008. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Rosenberg S. A., Lotze M. T., Yang J. C., Topalian S. L., Chang A. E., Schwartzentruber D. J., Aebersold P., Leitman S., Linehan W. M., Seipp C. A. Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer. J Natl Cancer Inst. 1993 Apr 21;85(8):622–632. doi: 10.1093/jnci/85.8.622. [DOI] [PubMed] [Google Scholar]
- Sogabe K., Nirei H., Shoubo M., Nomoto A., Ao S., Notsu Y., Ono T. Pharmacological profile of FR139317, a novel, potent endothelin ETA receptor antagonist. J Pharmacol Exp Ther. 1993 Mar;264(3):1040–1046. [PubMed] [Google Scholar]
- Vemulapalli S., Chiu P. J., Griscti K., Brown A., Kurowski S., Sybertz E. J. Phosphoramidon does not inhibit endogenous endothelin-1 release stimulated by hemorrhage, cytokines and hypoxia in rats. Eur J Pharmacol. 1994 May 12;257(1-2):95–102. doi: 10.1016/0014-2999(94)90699-8. [DOI] [PubMed] [Google Scholar]
- Vemulapalli S., Chiu P. J., Rivelli M., Foster C. J., Sybertz E. J. Modulation of circulating endothelin levels in hypertension and endotoxemia in rats. J Cardiovasc Pharmacol. 1991 Dec;18(6):895–903. doi: 10.1097/00005344-199112000-00017. [DOI] [PubMed] [Google Scholar]
- Vial T., Descotes J. Clinical toxicity of interleukin-2. Drug Saf. 1992 Nov-Dec;7(6):417–433. doi: 10.2165/00002018-199207060-00004. [DOI] [PubMed] [Google Scholar]
- Warner T. D., Battistini B., Doherty A. M., Corder R. Endothelin receptor antagonists: actions and rationale for their development. Biochem Pharmacol. 1994 Aug 17;48(4):625–635. doi: 10.1016/0006-2952(94)90038-8. [DOI] [PubMed] [Google Scholar]
- Watanabe T., Suzuki N., Shimamoto N., Fujino M., Imada A. Contribution of endogenous endothelin to the extension of myocardial infarct size in rats. Circ Res. 1991 Aug;69(2):370–377. doi: 10.1161/01.res.69.2.370. [DOI] [PubMed] [Google Scholar]
- Watanabe T., Suzuki N., Shimamoto N., Fujino M., Imada A. Endothelin in myocardial infarction. Nature. 1990 Mar 8;344(6262):114–114. doi: 10.1038/344114a0. [DOI] [PubMed] [Google Scholar]
- Yoshimi H., Kawano Y., Akabane S., Ashida T., Yoshida K., Kinoshita O., Kuramochi M., Omae T. Immunoreactive endothelin-1 contents in brain regions from spontaneously hypertensive rats. J Cardiovasc Pharmacol. 1991;17 (Suppl 7):S417–S419. doi: 10.1097/00005344-199100177-00118. [DOI] [PubMed] [Google Scholar]